Oncology Impact Fund (Cayman) Management L.P., 10% Owner at iTeos Therapeutics, Inc. (ITOS), sold 76,632 shares at $35.49 ($2.7M) on 2021-11-26, disclosed to the SEC on 2021-11-30.
Open-market sale of $2.7M ITOS by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.49 | 10,952 | $389K | 14.4% |
| 2 | $35.49 | 10,952 | $389K | 14.4% |
| 3 | $36.03 | 10,258 | $370K | 13.7% |
| 4 | $36.03 | 10,258 | $370K | 13.7% |
| 5 | $34.46 | 16,856 | $581K | 21.5% |
| 6 | $34.46 | 16,856 |
| $581K |
| 21.5% |
| 7 | $35.37 | 500 | $18K | 0.7% |
| Total | $35.18 avg | 76,632 | $2.7M | 100% |
| Filing → |
| ITOS | SELL | 2021-10-18 | $1.6M | — | Filing → |
| ITOS | SELL | 2021-10-12 | $4.6M | — | Filing → |
| ITOS | SELL | 2021-09-20 | $8.7M | — | Filing → |